Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emmaus Life Sciences, Inc.MYND · Entity 205 | Director · 10% owner | May 23, 2019 | May 23, 2019 |
| HOOPER HOLMES INCHH · Entity 161766 | 10% owner | March 03, 2017 | April 21, 2017 |
| Telemynd, Inc.NONE · Entity 155932 | Director · 10% owner | July 16, 2019 | July 18, 2019 |
| Vyant Bio, Inc.CGIX · Entity 116415 | Director | January 31, 2019 | February 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emmaus Life Sciences, Inc.
Report date May 23, 2019 · Filed May 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 1,117,925 |
Reported balance
After 2019-05-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-05-23 · Purchase · Acquired 200,000 · Balance 1,117,925 F1: Does not include 15,000 restricted shares that are subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Does not include 15,000 restricted shares that are subject to vesting.
HOOPER HOLMES INC
Report date March 03, 2017 · Filed April 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,592,421 |
Reported balance
Holding disclosure · report date 2017-03-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,592,421 |
| Warrants (rights to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2021-03-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-03 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed |
Telemynd, Inc.
Report date July 16, 2019 · Filed July 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,132,925 |
Reported balance
After 2019-07-16 transaction · row 1
1 source rowRow 1 · 2019-07-16 · Other · Acquired 1,132,925 · Balance 1,132,925 F1: Telemynd, Inc. ("Telemynd") was formerly a wholly-owned subsidiary of MYnd Analytics, Inc. ("MYnd"). On July 15, 2019, pursuant to the Amended and Restated Separation and Distribution Agreement, dated as of March 27, 2019, between MYnd and Telemynd, the Reporting Person received a pro rata distribution of common stock of Telemynd. |
| Series A Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,000,000 |
Reported balance
After 2019-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-16 · Other · Acquired 1,000,000 · Balance 1,000,000 F2: The reporting person received his shares of Series A Preferred Stock pursuant to an Exchange Agreement with MYnd and Telemynd. under which he exchanged previously held securities for shares of Series A Preferred Stock. F3: The shares of Series A Preferred Stock have no expiration date and are convertible at any time at the election of the Reporting Person without payment of further consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Telemynd, Inc. ("Telemynd") was formerly a wholly-owned subsidiary of MYnd Analytics, Inc. ("MYnd"). On July 15, 2019, pursuant to the Amended and Restated Separation and Distribution Agreement, dated as of March 27, 2019, between MYnd and Telemynd, the Reporting Person received a pro rata distribution of common stock of Telemynd.
F2: The reporting person received his shares of Series A Preferred Stock pursuant to an Exchange Agreement with MYnd and Telemynd. under which he exchanged previously held securities for shares of Series A Preferred Stock.
F3: The shares of Series A Preferred Stock have no expiration date and are convertible at any time at the election of the Reporting Person without payment of further consideration.
Vyant Bio, Inc.
Report date January 31, 2019 · Filed February 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 4,781,204 |
Reported balance
After 2019-01-31 transaction · row 1
1 source rowRow 1 · 2019-01-31 · Purchase · Acquired 1,000,000 · Balance 4,781,204 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2017 Filed Apr 21, 2017 17:19 UTC | HOOPER HOLMES INC HH · Entity 161766 | PurchaseCommon Stock | 15,852 | $0.74 | $11,795.47 |
DisclosureSEC source: 0001615774-17-001821 · s105933_form4.xml · nonDerivative · entry 2 PAPPAJOHN JOHN · CIK 0000897464 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 1,708,273 Read SEC document |
| March 09, 2017 Filed Apr 21, 2017 17:19 UTC | HOOPER HOLMES INC HH · Entity 161766 | PurchaseCommon Stock | 100,000 | $0.73 | $72,660.00 |
DisclosureSEC source: 0001615774-17-001821 · s105933_form4.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,692,421 Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 21:01 UTC | Emmaus Life Sciences, Inc. MYAN · Entity 205 | GrantCommon Stock | 32,000 | $6.25 | $200,000.00 |
DisclosureSEC source: 0001615774-17-000591 · s105338_form4.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,412 F1 · kind: Purchased in a private placement of securities by the issuer. Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 22:47 UTC | Emmaus Life Sciences, Inc. MYAN · Entity 205 | GrantCommon Stock | 16,000 | $6.25 | $100,000.00 |
DisclosureSEC source: 0001615774-16-009121 · s105051_form4.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,412 F1 · kind: Purchased in a private placement of securities by the issuer. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 21:36 UTC | Emmaus Life Sciences, Inc. MYAN · Entity 205 | GrantCommon Stock | 32,000 | $6.25 | $200,000.00 |
DisclosureSEC source: 0001615774-16-008687 · s104848_johnpappajohn.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,412 F1 · kind: Purchased in a private placement of securities by the issuer. Read SEC document |
| November 28, 2016 Filed Nov 29, 2016 17:13 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $1.45 | $145,280.00 |
DisclosureSEC source: 0001349929-16-000134 · wf-form4_148045759216252.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,420,709 Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 16:06 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | PurchaseCommon Stock, par value $0.0001 per share | 31,100 | $1.48 | $46,049.77 |
DisclosureSEC source: 0001349929-16-000128 · wf-form4_147933035263436.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,320,709 Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 01:49 UTC | Emmaus Life Sciences, Inc. MYAN · Entity 205 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-16-007992 · s104519_form4.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,412 F1 · date: The award was recommended by the compensation committee and approved by the board of directors of MYnd Analytics, Inc. (the "Registrant") on September 22, 2016, subject to stockholder approval of the Amended and Restated 2012 Omnibus Incentive Compensation Plan (the "Plan") under which the award was granted. The Registrant's stockholders approved the Plan on November 1, 2016. Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 20:35 UTC | Emmaus Life Sciences, Inc. MYAN · Entity 205 | PurchaseCommon Stock | 200 | $8.50 | $1,700.00 |
DisclosureSEC source: 0001615774-16-007718 · s104379_form4.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,412 Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:30 UTC | Emmaus Life Sciences, Inc. MYAN · Entity 205 | PurchaseCommon Stock | 1,000 | $8.00 | $8,000.00 |
DisclosureSEC source: 0001615774-16-007679 · s104359_form4.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,212 Read SEC document |
| October 12, 2016 Filed Oct 14, 2016 20:30 UTC | Emmaus Life Sciences, Inc. MYAN · Entity 205 | PurchaseCommon Stock | 16 | $7.50 | $120.00 |
DisclosureSEC source: 0001615774-16-007625 · s104336_form4.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,212 Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 16:28 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001349929-16-000116 · wf-form4_147639051105560.xml · derivative · entry 2 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.0001 per share · 10,000 shares Expires 2026-10-11 F2 · derivative.exercise_date: The option vests in two equal installments on October 11, 2017 and October 11, 2018, respectively. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 16:28 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantCommon Stock, par value $0.0001 per share | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001349929-16-000116 · wf-form4_147639051105560.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,289,609 F1 · shares: The restricted stock underlying the award vests in two equal installments on October 11, 2017 and October 11, 2018, respectively. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 20:09 UTC | Emmaus Life Sciences, Inc. MYAN · Entity 205 | PurchaseCommon Stock | 1,839 | $6.45 | $11,866.52 |
DisclosureSEC source: 0001615774-16-007600 · s104325_form4.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,196 Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 22:25 UTC | Emmaus Life Sciences, Inc. CNSO · Entity 205 | Disposition to issuerCommon Stock Warrant · Derivative | Not disclosed | Not disclosed Strike: $10.00 | $1,400,000.00 |
DisclosureSEC source: 0001615774-16-007362 · s104194_form4.xml · derivative · entry 3 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,000 shares Expires 2020-12-31 F1 · security: All information provided herein has been adjusted where necessary to give effect to the 1-for-200 reverse stock split effected on September 21, 2016. F4 · kind: The Amendment provided that upon the conversion of the notes issued pursuant to the Note and Warrant Purchase Agreement, which was caused by the Issuer on September 21, 2016, all warrants issued pursuant to the Note and Warrant Purchase Agreement would be cancelled. F4 · price: The Amendment provided that upon the conversion of the notes issued pursuant to the Note and Warrant Purchase Agreement, which was caused by the Issuer on September 21, 2016, all warrants issued pursuant to the Note and Warrant Purchase Agreement would be cancelled. F5 · derivative.exercise_date: The Common Stock Warrants were exercisable as of their respective dates of issuance. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 22:25 UTC | Emmaus Life Sciences, Inc. CNSO · Entity 205 | Exercise / conversion5% Secured Convertible Note due December 2017 · Derivative | Not disclosed | Not disclosed Strike: $5.00 | $1,400,000.00 |
DisclosureSEC source: 0001615774-16-007362 · s104194_form4.xml · derivative · entry 2 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 290,498 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All information provided herein has been adjusted where necessary to give effect to the 1-for-200 reverse stock split effected on September 21, 2016. F2 · reported_value: Seven notes in the aggregate principal amount of $1,400,000 were purchased by the Reporting Person between September 22, 2014 and August 9, 2016 pursuant to a Note and Warrant Purchase Agreement, dated as of September 22, 2014, as amended (the "Note and Warrant Purchase Agreement"), between the Issuer and the investors party thereto. These notes were convertible by the Reporting Person starting December 16, 2017 through December 31, 2017. F3 · reported_value: On September 19, 2016, the Issuer entered into a Second Omnibus Amendment (the "Amendment") between the Issuer and the investors party thereto, to the Note and Warrant Purchase Agreement, which granted the Issuer the option, exercisable at any time after September 1, 2016, to mandatorily convert all notes issued pursuant to the Note and Warrant Purchase Agreement into shares of the Issuer's common stock at $5.00 per share (subject to certain adjustments) (the "Mandatory Conversion"). On September 19, 2016, the Issuer exercised its Mandatory Conversion option under the Amendment, and on September 21, 2016 caused the conversion of $1,400,000 in aggregate principal amount of the Reporting Person's notes, with accrued interest thereon of $52,486.98, at a conversion price of $5.00 per share of common stock. F2 · price: Seven notes in the aggregate principal amount of $1,400,000 were purchased by the Reporting Person between September 22, 2014 and August 9, 2016 pursuant to a Note and Warrant Purchase Agreement, dated as of September 22, 2014, as amended (the "Note and Warrant Purchase Agreement"), between the Issuer and the investors party thereto. These notes were convertible by the Reporting Person starting December 16, 2017 through December 31, 2017. F3 · price: On September 19, 2016, the Issuer entered into a Second Omnibus Amendment (the "Amendment") between the Issuer and the investors party thereto, to the Note and Warrant Purchase Agreement, which granted the Issuer the option, exercisable at any time after September 1, 2016, to mandatorily convert all notes issued pursuant to the Note and Warrant Purchase Agreement into shares of the Issuer's common stock at $5.00 per share (subject to certain adjustments) (the "Mandatory Conversion"). On September 19, 2016, the Issuer exercised its Mandatory Conversion option under the Amendment, and on September 21, 2016 caused the conversion of $1,400,000 in aggregate principal amount of the Reporting Person's notes, with accrued interest thereon of $52,486.98, at a conversion price of $5.00 per share of common stock. F2 · derivative.exercise_date: Seven notes in the aggregate principal amount of $1,400,000 were purchased by the Reporting Person between September 22, 2014 and August 9, 2016 pursuant to a Note and Warrant Purchase Agreement, dated as of September 22, 2014, as amended (the "Note and Warrant Purchase Agreement"), between the Issuer and the investors party thereto. These notes were convertible by the Reporting Person starting December 16, 2017 through December 31, 2017. F3 · derivative.exercise_date: On September 19, 2016, the Issuer entered into a Second Omnibus Amendment (the "Amendment") between the Issuer and the investors party thereto, to the Note and Warrant Purchase Agreement, which granted the Issuer the option, exercisable at any time after September 1, 2016, to mandatorily convert all notes issued pursuant to the Note and Warrant Purchase Agreement into shares of the Issuer's common stock at $5.00 per share (subject to certain adjustments) (the "Mandatory Conversion"). On September 19, 2016, the Issuer exercised its Mandatory Conversion option under the Amendment, and on September 21, 2016 caused the conversion of $1,400,000 in aggregate principal amount of the Reporting Person's notes, with accrued interest thereon of $52,486.98, at a conversion price of $5.00 per share of common stock. F2 · derivative.underlying_shares: Seven notes in the aggregate principal amount of $1,400,000 were purchased by the Reporting Person between September 22, 2014 and August 9, 2016 pursuant to a Note and Warrant Purchase Agreement, dated as of September 22, 2014, as amended (the "Note and Warrant Purchase Agreement"), between the Issuer and the investors party thereto. These notes were convertible by the Reporting Person starting December 16, 2017 through December 31, 2017. F3 · derivative.underlying_shares: On September 19, 2016, the Issuer entered into a Second Omnibus Amendment (the "Amendment") between the Issuer and the investors party thereto, to the Note and Warrant Purchase Agreement, which granted the Issuer the option, exercisable at any time after September 1, 2016, to mandatorily convert all notes issued pursuant to the Note and Warrant Purchase Agreement into shares of the Issuer's common stock at $5.00 per share (subject to certain adjustments) (the "Mandatory Conversion"). On September 19, 2016, the Issuer exercised its Mandatory Conversion option under the Amendment, and on September 21, 2016 caused the conversion of $1,400,000 in aggregate principal amount of the Reporting Person's notes, with accrued interest thereon of $52,486.98, at a conversion price of $5.00 per share of common stock. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 22:25 UTC | Emmaus Life Sciences, Inc. CNSO · Entity 205 | Exercise / conversionCommon Stock | 290,498 | $5.00 | $1,452,490.00 |
DisclosureSEC source: 0001615774-16-007362 · s104194_form4.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All information provided herein has been adjusted where necessary to give effect to the 1-for-200 reverse stock split effected on September 21, 2016. Read SEC document |
| September 16, 2016 Filed Sep 21, 2016 00:24 UTC | Emmaus Life Sciences, Inc. CNSO · Entity 205 | GiftCommon Stock | 6,538,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-16-007288 · s104171_form4.xml · nonDerivative · entry 1 PAPPAJOHN JOHN · CIK 0000897464 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,571,699 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.